CSIMarket
 


Revolution Medicines Inc   (RVMD)
Other Ticker:  
 
 

RVMD's Income from Cont. Operations Growth by Quarter and Year

Revolution Medicines Inc 's Income from Cont. Operations results by quarter and year




RVMD Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -56.51 -52.68 -34.20
III Quarter September -108.43 -73.33 -52.94 -27.22
II Quarter June -98.30 -61.22 -44.30 -27.22
I Quarter March -68.10 -57.65 -37.18 -21.74
FY   -274.83 -248.71 -187.10 -110.38



RVMD Income from Cont. Operations third quarter 2023 Y/Y Growth Comment
Revolution Medicines Inc in the third quarter 2023 recorded loss from continued operations of $ -108.43 millions.

According to the results reported in the third quarter 2023, Revolution Medicines Inc achieved the best Income from Cont. Operations growth in Biotechnology & Pharmaceuticals industry. While Revolution Medicines Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2023.




RVMD Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Revolution Medicines Inc 's third quarter 2023 Income from Cont. Operations $ -108.43 millions RVMD's Income Statement
Revolution Medicines Inc 's third quarter 2022 Income from Cont. Operations $ -73.33 millions Quarterly RVMD's Income Statement
New: More RVMD's historic Income from Cont. Operations Growth >>


RVMD Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Revolution Medicines Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RVMD's III. Quarter Q/Q Income from Cont. Operations Comment
Recent results of -108.43 millions by Revolution Medicines Inc appear even more unfavourable compare to the -98.30 millions in the previous quarter.

Within Biotechnology & Pharmaceuticals industry Revolution Medicines Inc achieved highest sequential Income from Cont. Operations growth. While Revolution Medicines Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RVMD's III. Quarter Q/Q Income from Cont. Operations Comment
III. Quarter 2023 results of -108.43 millions by Revolution Medicines Inc look even more unfavourable considering the loss from continued operations -98.30 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Revolution Medicines Inc achieved highest sequential Income from Cont. Operations growth. While Revolution Medicines Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Revolution Medicines Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -331.34 $ -296.23 $ -259.16 $ -248.71 $ -244.87
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Revolution Medicines Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -331 millions in the Sep 30 2023 period.
The results are getting worse as the cumulative loss from continued operations is inflating from $ -296.23 millions for the period from Jun 30 2023 to Sep 30 2022 and $ -224.485 millions for the twelve months ending in the quarter Sep 30 2022.

Revolution Medicines Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Revolution Medicines Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -331 millions in the Sep 30 2023 period.
The business is detiriorating as the cumulative loss from continued operations is getting bigger from $ -296.23 millions in TTM ending quarter Jun 30 2023 and $ -224.485 millions for the twelve months ending in the quarter a year ago.

Revolution Medicines Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
RVMD's Income from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for RVMD's Competitors
Income from Cont. Operations Growth for Revolution Medicines Inc 's Suppliers
Income from Cont. Operations Growth for RVMD's Customers

You may also want to know
RVMD's Annual Growth Rates RVMD's Profitability Ratios RVMD's Asset Turnover Ratio RVMD's Dividend Growth
RVMD's Roe RVMD's Valuation Ratios RVMD's Financial Strength Ratios RVMD's Dividend Payout Ratio
RVMD's Roa RVMD's Inventory Turnover Ratio RVMD's Growth Rates RVMD's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2023
Integer Holdings Corporation69.75%$ 69.752 millions
Merit Medical Systems Inc69.16%$ 69.159 millions
Align Technology inc 67.02%$ 67.025 millions
Select Medical Holdings Corp59.51%$ 59.513 millions
Infusystem Holdings Inc 55.53%$ 55.530 millions
Incyte Corporation51.87%$ 51.868 millions
Teva Pharmaceutical Industries Limited51.72%$ 51.724 millions
Semler Scientific Inc 50.04%$ 50.041 millions
Iradimed Corporation47.86%$ 47.856 millions
Merck and Co Inc 46.02%$ 46.019 millions
Lftd Partners Inc 45.85%$ 45.849 millions
Msa Safety Incorporated45.32%$ 45.317 millions
Option Care Health Inc 45.02%$ 45.022 millions
Ir med Inc 37.73%$ 37.734 millions
Lemaitre Vascular Inc 37.50%$ 37.500 millions
Becton Dickinson And Company36.61%$ 36.607 millions
Encompass Health Corporation34.15%$ 34.152 millions
West Pharmaceutical Services Inc 33.75%$ 33.748 millions
Addus Homecare Corporation33.51%$ 33.509 millions
Halozyme Therapeutics Inc 32.78%$ 32.779 millions
Chemed Corporation31.80%$ 31.799 millions
Intuitive Surgical Inc 29.29%$ 29.289 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com